Catalyst Wire Dossier Catalyst Wire Dossier

Genome-edited autologous hematopoietic stem and progenitor cells (HSPCs)

· Novartis Pharmaceuticals
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Genome-edited autologous hematopoietic stem and progenitor cells (HSPCs), covering 2025-10-03 to 2025-10-03. Get the full timeline:

Most recent: Clinical Trial Update: Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC) [Phase 1]

See pricing